张宏
一、个人简介
张宏，博士，教授，邮箱：zhanghong@chnu.edu.cn
国家科技部科技专家库专家，国家自然科学基金评审专家，教育部学位与研究生教育发展中心评审专家，中国教育发展战略学会人才发展专业委员会学术桥专家库专家，上海市和北京市科技专家库专家，上海市浦东新区领先人才；世界中医药学会联合会道地药材多维评价专业委员会常务理事。入选2023和2024年全球前2%科学家榜单及2023年中国高被引学者名单。Current Pharmaceutical Design杂志编委和Frontiers in Pharmacology杂志客座编辑。
长期从事中药复方药理研究，2023年提出的“如何阐明方剂君臣佐使配伍的科学内涵”被中华中医药学会遴选为中医药重大科学问题（中医杂志，2023，64（14）：1405-1421），并于2024年提出基于疾病微环境的成分配伍研究策略（中国科学：生命科学，2024，54（5）：911-924）。还先后提出“成分中药”的概念及发现方法（国作登字-2023-A-00319790；Journal of Ethnopharmacology，2020, 254: 112687），中医“证候”与西医“疾病”具有共同的分子病理基础（Current Pharmaceutical Design，2016, 22(3): 312-320），中药应以临床功效为导向进行质量标准研究（中华中医药杂志，2014，29(12): 3686-3688）等观点。
先后主持国家和省部级等纵向课题16项，包括国家自然科学基金面上项目3项，国家重点研发计划子课题1项；获得中药新药临床批件1项，开发中药院内制剂5个；授权国家发明专利11项；编写专著和教材，副主编4部，编委6部；发表论文160余篇，其中以第一作者或通讯作者发表SCI论文86篇，核心期刊36篇，全球高被引SCI论文2篇，总引用7000余次，H指数46。
二、主要科研成果
1、近五年承担的科研项目
[1] 安徽省科技创新攻坚计划重点项目子课题，候选药物Bufotlin诱导肺癌细胞凋亡的作用靶点研究，2024/09/9-2027/09/09，24万元，在研，主持
[2] 国家自然科学基金面上项目，中药苦荞头有效成分Tatariside F靶向MZF1/lncRNA HClnc1/ODC1通路抗肝癌的分子机制研究，2022/01-2025/12，55万元，在研，主持
[3] 国家重点研发计划子课题，三种小血管病“异病同证”物质基础及复方“异病同治”药理作用研,究2019/12-2022/06，216万元，结题，主持
[4] 国家自然科学基金面上项目，基于细胞热转移分析技术的蔓荆呋喃诱导宫颈癌细胞凋亡分子靶点研究，2018/01-2021/12，55万元，结题，主持
2、近五年代表性论文
[1] 张宏*，李奇璋，刘爱芬，曾克武，丁显廷，王博谦，史建伍，王成牛，辛海量，张磊*. 基于成分配伍的中药复方研究策略. 中国科学:生命科学，2024，54（5）：911-924.
[2] Yi-Qing Deng, Min Gao, Dong Lu, Qiu-Ping Liu, Run-Jing Zhang, Ji Ye, Jing Zhao, Zhi-Hui Feng, Qi-Zhang Li*, Hong Zhang*. Compound-composed Chinese medicine of Huachansu triggers apoptosis of gastric cancer cells through increase of reactive oxygen species levels and suppression of proteasome activities. Phytomedicine, 2024, 123: 155169.
[3] Qi-Zhang Li, Yu-Ying Chen, Qiu-Ping Liu, Zhi-Hui Feng, Lei Zhang*, Hong Zhang*. Cucurbitacin B suppresses hepatocellular carcinoma progression through inducing DNA damage-dependent cell cycle arrest. Phytomedicine, 2024, 126: 155177.
[4] 邢一卓，杨鸿轩，邓仪卿，张宏*. 模拟肿瘤微环境的多细胞共培养肿瘤球模型在药物研究中的应用. 中华中医药杂志，2023，38（12）：5925-5932.
[5] Qiu-Ping Liu, Yu-Ying Chen, Pei An, Khalid Rahman, Xin Luan*, Hong Zhang*. Natural products targeting macrophages in tumor microenvironment are a source of potential antitumor agents. Phytomedicine, 2023, 109: 154612.
[6] Pei An, Dong Lu, Lijun Zhang, Haiyue Lan, Hongxuan Yang, Guangbo Ge, Wei Liu, Weixing Shen, Xianting Ding, Dongxin Tang, Weidong Zhang, Xin Luan*, Haibo Cheng*, Hong Zhang*. Synergistic antitumor effects of compound-composed optimal formula from Aidi injection on hepatocellular carcinoma and colorectal cancer. Phytomedicine, 2022, 103:154231.
[7] Yu-Ying Chen, Qiu-Ping Liu, Pei An, Min Jia, Xin Luan*, Jian-Yuan Tang*, Hong Zhang*. Ginsenoside Rd: A promising natural neuroprotective agent. Phytomedicine, 2022, 95:153883.
[8] Wen-Qing Li, Wen-Hao Liu, Die Qian, Jia Liu, Shi-Qiong Zhou, Lei Zhang, Wei Peng*, Li Su*, Hong Zhang*. Traditional Chinese medicine: an important source for discovering candidate agents against hepatic fibrosis. Frontiers in Pharmacology, 2022, 13: 962525.
[9] Qiu-Ping Liu, Jia-Yi Lin, Pei An, Yu-Ying Chen, Xin Luan*, Hong Zhang*. LncRNAs in tumor microenvironment: the potential target for cancer treatment with natural compounds and chemical drugs. Biochemical Pharmacology, 2021, 193:114802.
[10] Pei An, Li-Jun Zhang, Wei Peng, Yu-Ying Chen, Qiu-Ping Liu, Xin Luan*, Hong Zhang*. Natural products are an important source for proteasome regulating agents. Phytomedicine, 2021, 93: 153799.
[11] Yuan-Yuan Yu, Qiu-Ping Liu, Meng-Ting Li, Pei An, Yu-Ying Chen, Xin Luan*, Chao Lv*, Hong Zhang*. Hu-zhang-qing-mai-yin inhibits proliferation of human retinal microvascular endothelial cells exposed to high glucose. Frontiers in Pharmacology, 2021, 12: 732655.
[12] Ting Yang, Yi-Xin Jiang, Ye Wu, Dong Lu, Rui Huang, Long-Ling Wang, Shi-Qi Wang, Yingyun Guan*, Hong Zhang*, Xin Luan*. Resibufogenin suppresses triple-negative breast cancer angiogenesis by blocking VEGFR2-mediated signaling pathway. Frontiers in Pharmacology, 2021, 682735.
[13] Mengting Li, Jia Ke, Yiqing Deng, Chunxiang Chen, Yichen Huang, Yuefeng Bian, Shufen Guo, Yang Wu, Hong Zhang*, Mingyuan Liu*, Yan Han*. The protective effect of liquiritin in hypoxia/reoxygenation-induced disruption on blood brain barrier. Frontiers in Pharmacology, 2021, 671783.
[14] Hai-Yue Lan, Pei An, Qiu-Ping Liu, Yu-Ying Chen, Yuan-Yuan Yu, Xin Luan*, Jian-Yuan Tang*, Hong Zhang*. Aidi injection induces apoptosis of hepatocellular carcinoma cells through the mitochondrial pathway. Journal of Ethnopharmacology, 2021, 274, 114073.
[15] Gang Gong, Ying-Yun Guan, Zhong-Lin Zhang, Khalid Rahman, Su-Juan Wang, Shuang Zhou*, Xin Luan*, Hong Zhang*. Isorhamnetin: A review of pharmacological effects. Biomedicine & Pharmacotherapy, 2020, 128: 110301.
[16] Xin Luan, Li-Jun Zhang, Xiao-Qin Li, Khalid Rahman, Hong Zhang*, Hong-Zhuan Chen*, Wei-Dong Zhang*. Compound-based Chinese medicine formula: From discovery to compatibility mechanism. Journal of Ethnopharmacology, 2020, 254: 112687.